Résultats de la recherche
10
Tout
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219
20 mars 2025 07h00 HE
|
Sitryx Therapeutics
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
07 mars 2025 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD).
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
28 févr. 2025 09h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that it will present two posters at the 2025 AAD annual meeting which will take place in Orlando, FL, from March 7-11, 2025.
Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug
26 févr. 2025 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
26 févr. 2025 08h00 HE
|
Arcutis Biotherapeutics, Inc.
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
24 févr. 2025 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old
Dermatology Excimer Laser Market Research and Forecasts 2023-2024 & 2024-2034: Growing Trend Toward Specialized Centers Focused on Advanced Dermatological Treatments
29 janv. 2025 11h05 HE
|
Research and Markets
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Excimer Laser Market by Product, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
16 déc. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the submission of an sNDA to the FDA for ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 for mild to moderate AD.
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
13 nov. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Dermatology Treatment and Care Research Report 2024-2030 with Analyst Recommendations - Tapping into the Demand for Tailored Solutions / Focus on Expansion in Emerging Markets
29 oct. 2024 05h01 HE
|
Research and Markets
Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatology Treatment and Care Market (2024 Edition): Analysis By Treatment Type (Skin Disease and Care, Hair Disease and Care), By Route of...